<DOC>
	<DOCNO>NCT00453986</DOCNO>
	<brief_summary>The purpose study demonstrate , 18-55 year old adult , consistency different manufacture lots meningococcal vaccine GSK134612 , non-inferiority GSK134612 compare license meningococcal vaccine Mencevax™ , non-inferiority GSK134612 give experimental co-administration Fluarix™ compare GSK134612 give alone immunogenicity GSK134612 give Fluarix™ . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Lot Consistency , Immuno , Safety Meningococcal Vaccine GSK134612 Given With Fluarix™ 18-55 Year-Old Adults</brief_title>
	<detailed_description>Multicentre study 5 treatment group . Three group receive three different manufacture lot GSK134612 , one group receive one lot GSK134612 give experimental co-administration Fluarix™ , control group receive Mencevax™ . The study conduct double-blind manner respect 3 lot GSK134612 vaccine . The study 'open ' group receive GSK134612 group receive GSK134612 + Fluarix™ Mencevax™ group . Each subject 2 blood sample take immunogenicity analyse , one prior vaccination one take 30 day later .</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>For subject : Subjects investigator believe comply requirement protocol . A male female , include , 18 55 year age time vaccination . Written inform consent obtain subject . Healthy subject establish medical history clinical examination enter study . Previously complete routine childhood vaccination best his/her knowledge . If subject female , must nonchildbearing potential , childbearing potential , must practice adequate contraception 30 day prior vaccination , negative pregnancy test , continue precaution 2 month completion vaccination series . For subject : Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede dose study vaccine , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior vaccine dose . Planned administration/ administration vaccine foreseen study protocol within one month dose vaccine ( ) . Previous vaccination meningococcal polysaccharide vaccine serogroup A , C , W , and/or Y within last five previous year . Previous vaccination meningococcal polysaccharide conjugate vaccine serogroup A , C , W , and/or Y . Previous vaccination tetanus toxoid within last month . History meningococcal disease . Any confirm suspected immunosuppressive immunodeficient condition ( congenital secondary ) , include human immunodeficiency virus ( HIV ) infection , base medical history physical examination . A family history congenital hereditary immunodeficiency , immune competence potential vaccine recipient demonstrate . History reaction allergic disease likely exacerbate component vaccine . Major congenital defect serious chronic illness . Acute disease time enrolment . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period . Pregnant lactate female . History chronic alcohol consumption and/or drug abuse . Female plan become pregnant planning discontinue contraceptive precaution . Additional criterion subject receive Fluarix™ coadministration : History hypersensitivity previous dose influenza vaccine . History reaction allergy likely exacerbated component vaccine include egg , chicken protein , formaldehyde , thimerosal , gentamicin sulfate , sodium deoxycholate . History administration influenza vaccine outside study , current flu season .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>immunogenicity</keyword>
	<keyword>Meningococcal serogroups A , C , W-135 and/or Y disease</keyword>
	<keyword>co-administration</keyword>
	<keyword>meningococcal vaccine</keyword>
	<keyword>lot-to-lot consistency</keyword>
	<keyword>conjugate vaccine</keyword>
</DOC>